KR20150055792A - Novel Pediococcus pentosaceus sp. EP106 and Producing Method of Fermented Pueria Radix or Soy Hypocotyl using the Same - Google Patents

Abstract

The present invention relates to Pediococcuspentosaceus EP106 strains (accession number: KACC91829P) capable of converting daidzein or genistein respectively to dihydrodaidzein (DHD) or dihydrogenistein (DHG). The present invention also relates to a method for preparing fermented soybean embryo (Glycine max) or arrow root (Pueraria thunbergiana) by using the same.

Description

A novel Pediococcus pentosaceus EP106 strain and a method for producing a fermented soybean or soybean fermented product using the same, and a method for producing the fermented product of Novel Pediococcus pentosaceus sp. EP106 and Producing Method of Fermented Pueria Radix or Soy Hypocotyl using the Same}

The present invention relates to a novel strain of Pediococcus pentosaceus and a process for producing a fermented soybean or soybean fermented product using the same.

칡 (Pueria Radix) is a wild plant distributed in Korea, Japan, China, etc. It is a leguminosae plant used as a crab food from whales because of its high starch content. It is caulked and dried in early spring or late autumn, It has been reported that it controls hypertension, angina pectoris, diabetes, hangover, etc. It has been reported that antioxidant effect and interpolation effect are effective.

In addition, the soybean embryo itself is not used as it is, and most of it is discarded.

In particular, it has been known that the 칡 or soybean embryo has a moving flavone substance such as daidzin, daidzein, and genistein, and various uses have been developed for the extract.

Isoflavone, such as daidzin, daidzein, and genistein, has a chemical structure similar to estrogen and has a higher uptake in the body than other substances, and has excellent binding properties to estrogen receptors It has been reported that estrogen has a regulatory effect on the receptor. However, recent studies and researches have been carried out in the field of related research, as the major substances involved in the improvement of menopausal symptoms have recently been identified as isoflavones metabolized by intestinal microorganisms, rather than isoflavones themselves.

In this connection, Korean Patent Laid-Open Publication No. 2011-7008760, for example, discloses a method for producing isoflavones from bean sprouts.

However, since these strains are used only under anaerobic conditions, they have a limitation in culturing due to low microbial bio-conversion (productivity). Therefore, microorganisms that produce metabolites of isoflavones under aerobic conditions, fermentation broth and fermented extract It is a reality that needs development of Korea.

KR 10-2011-7008760 A

SUMMARY OF THE INVENTION The present invention has been made to solve the above-mentioned problems occurring in the prior art,

A novel strain capable of converting daidzein or genistein into dihydrodaidzein (DHD) or dihydrogenistein (DHG) under aerobic conditions, respectively, and using the same to produce a fermented soybean or soybean fermented product The present invention is directed to providing a method for providing a service to a user.

According to an aspect of the present invention,

Diadjene or genistein can be converted into dihydrodaidzein (DHD) or dihydrogenistein (DHG), respectively, by using Pediococcus pentosaceus ) EP106 (accession number: KACC91829P).

In addition, the present invention provides a method for producing a fermented product containing a dihydrolidase from a fermented milk extract using the strain.

In addition, the present invention provides a method for producing a dihydrogenentyne-containing soybean embryo fermented product from a soybean extract using the strain.

The present invention also provides a fermented product produced using the strain.

The present invention also provides a soybean embryo fermented product produced using the strain.

The present invention also provides a fermented fermented dried product prepared by freeze-drying the fermented product.

Also, the present invention provides a soybean embryo fermented frozen product prepared by freeze-drying the fermented soybean embryo.

The present invention also provides a pharmaceutical preparation comprising the above fermented product, which is used for the prevention or treatment of menopausal disorder, osteoporosis, prostate cancer, hypertrophy of the prostate gland or female hormone control disorder.

The present invention also provides a pharmaceutical preparation comprising the fermented soybean embryo used for the prevention or treatment of menopausal disorder, osteoporosis, or female hormone control disorder.

According to the method for producing the fermented soybean and soybean fermented product according to the present invention,

Dihydrodaidzein (DHD) or dihydrogenistein (DHG), which is an equol precursor having a function of preventing and treating female hormone related diseases such as osteoporosis, ) Can be produced under aerobic conditions by using 칡 or soybean embryo.

1 is a view showing the nucleotide sequence of the strain of the present invention.
2 is a graph showing changes in the DHD content of the fermented product according to an embodiment of the present invention.
FIG. 3 is a graph showing changes in DHD content of fermented products before and after fermentation according to an embodiment of the present invention.
FIG. 4 is a graph showing the ability of female fermented products to regulate female hormones according to an embodiment of the present invention.
FIG. 5 is a graph showing changes in DHG content of the fermented soybean embryo before and after fermentation according to an embodiment of the present invention. FIG.

To a process for producing a dihydrogenentyne-containing soybean embryo fermentation product from an extract.

Microorganisms used in the present invention The present invention will be described in detail below.

The present invention relates to Pediococcus pentosaceus EP106 (accession number: P104) capable of converting diidene or genistein to dihydrodaidzein (DHD) or dihydrogenistein (DHG), respectively, KACC91829P) and a method for producing a fermented product containing a dihydroididase from a mushroom extract using the same, and soybean is a strain of Pediococcus pentosaceus , which is obtained from the feces of a human by the inventors of the present invention EP106 (KACC91829P), which is an identified strain, has been deposited. In the present invention, the deposited strain may be used.

The method for producing the fermented product containing the dihydroididase,

(a) an extraction step of agitating and extracting the pulverized liquor with ethanol; And

(b) a culture step of inoculating the Pediococcus pentosaceus strain EP106 (accession number: KACC91829P) into the extract obtained in step (a) and stirring the same to prepare a culture solution.

The method for producing the fermented product containing the dihydroididase may use a raw material used in the (a) extraction step. There is no restriction as to whether or not the raw materials used in the present invention are produced or processed, as long as the raw materials, etc. contained therein are not destroyed. For example, untreated; Those separated from the furnace where the heat treatment, the drying treatment, the thickening treatment, etc. are performed; And a product obtained by separating the raw material from the raw material by heat treatment, drying treatment or thickening treatment, or the like. The shape of the foil used in the present invention is not particularly limited and may be a powder, a ground or a crushed, but it is preferable to use a powdery foil

The method for producing the fermented product containing the dihydroididase may use a polar solvent as the solvent used in the extraction step (a), more preferably ethanol. As the ethanol used in the present invention, ethanol is preferably used in an amount of 30% to 90% on the basis of alcohol for the efficiency of extraction.

In the method for producing the fermented product containing the dihydroididase, since aerobic strain is used, stirring is performed at a constant rate to supply oxygen. For this, the agitation speed of the culturing step (b) is preferably 100 to 300 rpm.

The method for producing the fermented product containing the dihydroidide is characterized in that the Pediococcus pentosaceus ) EP106 (Accession No .: KACC91829P) is inoculated into a culture medium and then cultured in aerobic fermentation for 20 to 80 hours in the temperature range in which the strain is able to grow. The temperature may be a condition suitable for growth, for example, 20 to 40 ?, preferably 35 to 40 ?, more preferably 36 to 38 ?.

The method for producing the fermented product containing dihydroididase according to the present invention preferably comprises 0.2 to 3% by weight based on the total amount of the extract extracted from the step (a) in the step (b).

In addition, the present invention provides a fermented product produced by using the strain Pediococcus pentosaceus EP106 (accession number: KACC91829P). Dihydrodaidzein (DHD) is formed and accumulated in the fermented product obtained by fermentation through the above steps. The fermented product obtained by the fermentation treatment under the above conditions can be used as a raw material for foods, medicines, cosmetics and the like as it is after the fermentation, and can be used as the raw material in a dry solid state, if necessary, in a dry solid state. (2) In order to improve the storage stability of the fermented product, it is desirable to make the fermented product solid by heating and drying treatment. The fermented product subjected to heat-drying treatment may be pulverized to a powder form if necessary.

Further, the method for producing the dihydrogenentyne-containing soybean embryo fermented product of the present invention comprises:

(a) an extraction step of extracting pulverized soybean with ethanol; And

(b) a culture step of inoculating the Pediococcus pentosaceus strain EP106 (accession number: KACC91829P) into the extract obtained in step (a) and stirring the same to prepare a culture solution.

The method for producing the dihydrogenentyne-containing soybean embryo fermented product may use a soybean embryo as a raw material used in the (a) extraction step. It is known that soybean embryo is a part which becomes infant and legume when germinating soybeans and contains a lot of isoflavones such as genistein. The soybean embryo used in the present invention is not limited as to whether the soybean is produced or not, as long as the contained genistein and the like are not lost. For example, untreated; Those separated from soybeans subjected to heat treatment, drying treatment, thickening treatment and the like; The embryo separated from the unprocessed soybeans may be treated with a heat treatment, a drying treatment or a thickening treatment or the like. In addition, the soybean embryo used in the present invention may be subjected to degreasing treatment or deproteinization treatment. The shape of the soybean embryo used in the present invention is not particularly limited, and it may be in the form of powder, pulverized or crushed, but it is preferable to use a powdered soybean embryo

The method for preparing the dihydrogenentyne-containing soybean embryo fermented product may use a polar solvent as the solvent used in the step (a), more preferably ethanol. As the ethanol used in the present invention, 20% to 80% of ethanol is preferably used on the basis of the alcohol for efficiency of extraction.

The method for producing the dihydrogenentyne-containing soybean embryo fermented product is such that aerobic strains are used so that oxygen is supplied by stirring at a constant rate. For this, the agitation speed of the culturing step (b) is preferably 100 to 300 rpm.

The method for producing the dihydrogenenisteine-containing soybean embryo fermentation product is characterized in that the Pediococcus pentosaceus ) EP106 (Accession No .: KACC91829P) is inoculated into a culture medium and then cultured in aerobic fermentation for 20 to 80 hours in the temperature range in which the strain is able to grow. The temperature may be a condition suitable for growth, for example, 20 to 40 占 폚, preferably 28 to 37 占 폚, and more preferably 25 to 30 占 폚.

The method for producing the dihydrogenentyne-containing soybean embryo fermented product preferably comprises 0.2 to 3% by weight based on the total amount of the culture medium extracted from the step (a) in the step (b).

The present invention also provides a soybean embryo fermented product produced using the strain Pediococcus pentosaceus EP106 (accession number: KACC91829P). Dihydrogenistein (DHG) is produced and accumulated in the fermented soybean embryo obtained by fermentation through the above steps. The fermented soybean embryo obtained by fermentation under the above conditions can be used as a raw material for foods, medicines, cosmetics and the like as it is after fermentation. In order to improve the storage stability of the fermented soybean embryo, it is preferable to make it solid by heat-drying treatment. The heat-dried soybean-embryo fermented product may be pulverized to a powder form if necessary.

Since the fermented product of the present invention and the fermented soybean embryo contain a useful physiologically active substance such as DHD as described above, various physiological activities and pharmacological activities can be expressed. For example, the fermented product of the present invention and the fermented product of soybean embryo are excellent in the control effect of the female hormone receptor at a higher concentration than general fungus, and have the characteristic of alleviating the cytotoxicity, so that it is safe for the human body, Which is useful for preventing or ameliorating the disease or symptom. In addition, the fermented product of the present invention and the fermented product of soybean embryo are useful for preventing or ameliorating symptoms associated with menopausal disorders or menopause, which are diseases related to female hormone control disorders, particularly in middle-aged women.

When the fermented product of the present invention and the fermented product of soybean embryo are used as a pharmaceutical material, the fermented product and the fermented product of the soybean embryo may be used in the form of tablets, pills, powders, solutions, suspensions, emulsions, granules, Suppositories, and the like. The pharmaceutical preparation containing the fermented product of the present invention and the fermented product of the soybean embryo is useful as a preventive or remedy for diseases and symptoms such as menopausal disorder, osteoporosis and the like. Particularly, the pharmaceutical preparation containing the fermented product and the fermented product of soybean embryo is preferably used for the prevention or treatment of symptoms accompanying boredom or menopause (for example, osteoporosis, menopausal disorder, etc.) in middle-aged women .

In order to more effectively apply such fermented product and soybean embryo fermented product, the present invention can provide the fermented fermented product and the soybean embryo fermented product by lyophilizing to prepare a fermented fermented product.

Hereinafter, the present invention will be described in more detail with reference to examples. However, the embodiments of the present invention described below are illustrative only and the scope of the present invention is not limited to these embodiments. The scope of the present invention is indicated in the claims, and moreover, includes all changes within the meaning and range of equivalency of the claims.

Example

 1. Identification of strain

For the first month, feces were collected from the feces of a person who consumed 칡 extract and applied to the medium of four kinds of gifu anaerobic medium (GAM), trypticase soy agar (TSA), ethylene bromide agar (EMA) and brain heart infusion (BHI) Each strain was isolated on the basis of the shape and color of the colony produced by incubation for 24 hours. In addition, the feces of people who ingested PGS for 2 weeks were divided into gifu anaerobic medium (GAM), trypticase soy agar (TSA), ethylene bromide agar (EMA), reinforced clostridial medium (RCM), brain heart infusion (BHI), Lactobacilli MRS (MRS) were sprinkled on 6 kinds of medium, and each strain was isolated based on the shape and color.

The isolated strains were analyzed by HPLC to confirm isoflavone metabolism producing strains. Genomic DNA was extracted using Solgent's genomic DNA prep kit to identify each isolate. Each primer contained a forward primer, 27F (5'-agagtttgatcMtggctcag-3 ', which specifically amplifies the 16S rRNA region of bacteria) ) And reverse primer 1492R (5'-ggYtaccttg ttacgactt-3 ') were used. PCR reaction mixture was prepared by mixing 1 μl of template, 10 μl of 2X Taq PCR premix (QIAGEN), 2 μl of forward primer (10 pmole / μl), 2 μl of reverse primer (10 pmole / μl) and 5 μl of dDW . The PCR cycle was performed at 94 ° C for 10 seconds, 45 ° C for 20 seconds, and 72 ° C for 1 minute, and the PCR procedure was repeated 30 times. In addition, the pre-denaturation procedure was performed at 94? For 2 minutes, the post-elongation procedure was performed at 72? For 5 minutes, and the PCR result was confirmed in 0.7% agarose gel. The purified product of the PCR product was purified using QIAquick Gel Extraction kit. The purified DNA was sequenced by Solgent for identification and analyzed using NCBI BLAST (Basic Local Alignment Search Tool) . The final isolate was Pediococcus pentosaceus , thus indicating that Pediococcus pentosaceus EP106, and deposited with the National Academy of Sciences on July 10, 2013 under accession number KACC91829P.

2. Preparation of 칡 extract and preparation of culture

The crude extracts were prepared in the same conditions as shown in Table 1 with a 20% alcohol (1:10 ratio), and filtered under reduced pressure using a filter paper (Hyundai micro, 20 μm) A rotary vacuum concentrator (EYELA, Japan) was used. Subsequently, 100 mL of GAM medium was placed in a 1 L Erlenmeyer flask, and the extract was inoculated into the medium under the same conditions as shown in Table 1, followed by inoculation with 0.1% of EP106 to prepare a culture.

At this time, the incubation time at the time of preparing the culture liquid, the incubation temperature at the time of preparing the culture liquid, the stirring speed at the time of preparing the culture liquid, and the content of the extract at the time of preparing the culture liquid were prepared as shown in Table 1 below.

Culture time (h) Culture temperature (캜) Stirring speed (rpm) Extract content (%) Example 1 24 28 250 1.5 Example 2 48 28 250 1.5 Example 3 72 28 250 1.5 Example 4 24 37 250 1.5 Example 5 48 37 250 1.5 Example 6 72 37 250 1.5 Example 7 48 28 100 1.5 Example 8 48 28 150 1.5 Example 9 48 28 200 1.5 Example 10 48 28 300 1.5 Example 11 48 28 250 0.1 Example 12 48 28 250 0.2 Example 13 48 28 250 0.5 Example 14 48 28 250 1.0 Example 15 48 28 250 2.0 Example 16 24 28 250 2.0

3. Preparation of soybean embryo extract and preparation of culture

The soybean embryo extract was prepared using the pulverized soybean embryo as a 20% alcohol (1:10 ratio) under the conditions shown in Table 2, and then filtered under reduced pressure using a filter paper (Hyundai micro, 20 μm) A rotary vacuum concentrator (EYELA, Japan) was used. Subsequently, 100 mL of GAM medium was placed in a 1 L Erlenmeyer flask, and the extract was inoculated into the medium under the same condition as shown in Table 2, and EP106 was inoculated 0.1% to prepare a culture.

At this time, the incubation time at the time of preparing the culture liquid, the incubation temperature at the time of preparing the culture liquid, the stirring speed at the time of producing the culture liquid, and the content of the extract at the time of producing the culture liquid were prepared as shown in Table 2 below.

Culture time (h) Culture temperature (캜) Stirring speed (rpm) Extract content (%) Example 17 24 28 250 1.5 Example 18 48 28 250 1.5 Example 19 72 28 250 1.5

4. Analysis conditions of the culture medium

DGU-20A3R (Shimazu, Japan) HPLC was used for the analysis of the culture, and the detector was measured at 280 nm with a PDA detector (Shimazu, SPD-M20A). Acetonitrile: acetic acid = 50: 50: 1 (v / v) for mobile phase A: water: acetic acid = 100: v%), a flow rate of 1 mL / min, a column oven at 40 ° C, and an injection volume of 50 μl. Injection samples were separated by centrifugation at 12,000 rpm for 15 min at 4 ° C.

3'-hydroxydaidzein (White amorphous powder); (1H, dd, J = 8.6, 2.2 Hz, H-6), 6.86 (2H, d, J = 8.6 Hz, d, J = 2.2 Hz, H-8), 6.94 (1H, dd, J = 8.6, 2.2 Hz, H- (1H, d, J = 8.6 Hz, H-5), 8.26 (1H, s, H-2).

8-O-methylretinine (White amorphous powder); (3H, s, OMe), 7.00 (2H, d, J = 8.6Hz, H-3 ', 5'), D, J = 8.5 Hz, H-5 (1H, d, J = ), 8.43 (1H, s, H-2).

Experimental Example  1: Depending on incubation temperature and time EP106 of DHD  output

In order to confirm the change in the production amount of DHD (dihydrodaidzein) according to the incubation temperature and time, the content of DHD was measured at 280 nm using the HPLC of the culture solutions of Examples 1 to 6. As shown in the following Table 3, DHD production of Example 2 cultured at 28 ° C for 48 hours was the highest.

DHD production (mg / g) Example 1 336.21 Example 2 490.45 Example 3 475.82 Example 4 5.55 Example 5 9.77 Example 6 18.60

Experimental Example  2: Difference in effect according to content of extract contained in culture

In order to confirm the change of the production amount depending on the content of the extract contained in the culture, the content of DHD was measured at 280 nm using the HPLC of the culture solutions of Examples 2, 11 to 15. As shown in FIG. 2, the amount of DHD produced in Example 15 having the content of 2% was the highest.

Experimental Example  3: Difference in effect according to oxygen concentration in culture

Using the fact that the concentration of oxygen contained in proportion to the stirring speed also increased when the culture liquid was stirred, in order to measure the change in the production amount of DHD according to the stirring speed, the culture medium of Examples 2, 7 to 10 , The content of DHD was measured at 280 nm using HPLC. As shown in Table 4 below, it was found that the content of DHD produced increases with increasing stirring speed. Thus, it was confirmed once again that the strain of the present invention is an aerobic strain.

Stirring speed DHD (mg / g) Example 10 300 rpm 221.4 Example 2 250 rpm 162.7 Example 9 200 rpm 156.5 Example 8 150 rpm 155.1 Example 7 100 rpm 132.2

Experimental Example  4: 칡 Fermented  Before and after fermentation DHD  Content measurement

As compared with the culture solution of Example 16, the extract of Phellinus linteus not inoculated with the EP106 culture of the present invention was regarded as Comparative Example 1. Fig. 3 compares the fermentation state before (before fermentation) (Comparative Example 1) and after fermentation (Example 16). As a result, about 50% of Daidzein contained in the extract was eliminated, and DHD (dihydrodaidzein), 3 -hydroxydaidzein (DHD) and 8-O-methylretusin (DHD) .

Experimental Example  5: 칡 Fermented  Measurement of female hormone receptor modulating effect

Using the EP 106 strain of the present invention, the female hormone receptor modulating effect was confirmed. The MCF-7 BUS cell line used in this experiment was purchased from Tufts University in the USA, and MG-63 cell line and LNCap cell line were purchased from Korean Cell Line Bank (KTCC, Korea). MCF-7 BUS cells were cultured in Dulbecco's fashion supplemented with 10% fetal bovine serum (Gibco, USA) and 1% penicillin / streptomycin (GIBCO, USA) modified eagle? (Gibco, USA) supplemented with 10% fetal bovine serum (Gibco, USA) and 1% penicillin / streptomycin (GIBCO, USA) were used for the MG-63 and LNCap cell lines. And cultured in a CO 2 incubator maintained at 37 ° C and 5% CO 2.

E-screen assay using MCF-7 BUS cell line is a method for measuring estrogen sensitivity. First, it is divided into 5 x 103 cells / well in a 96-well plate and incubated at 37 ° C in a CO2 incubator maintained at 5% . After 24 hours, the cells were changed to DMEM medium containing 10% of charcoaled FBS. At this time, the fermentation broth of Example 16 was treated at a concentration of 0.01 ug / mL to 100 ug / mL, and 17-estradiol (E2, Sigma, USA) was treated with 10-10 M as a positive control. The measurement was carried out at 550 nm using an ELISA reader (Tecan, Switzerland) using MTT (5 mg / mL) reagent after 72 hours and shown in FIG.

As shown in FIG. 4, when a synthetic hormone (17beta-estradiol, E2) was used as a positive control, the 20% extract of Pueraria lobata showed a higher concentration of MCF7-BUS Cells (breast cancer cell line) are suppressed and cytotoxicity is observed as the female hormone control effect disappears. However, when EP106 of the present invention is fermented under optimum conditions, the cell extract is not cytotoxic even at a high concentration, Receptor-modulating effect.

Therefore, it can be seen that when the fermented product prepared using the EP106 strain of the present invention is used, it is safer to the human body than the single substance, and at the same time, can help the female hormone-related diseases through regulating the female hormone receptor.

Experimental Example  6: soybean embryo Fermented  Depending on incubation time EP106 of DHG  output

In order to confirm the change in the production amount of dihydrogenistein (DHG) according to the incubation time of the fermented soybean embryo, the soybean embryo extract inoculated with the EP106 culture of the present invention was used as Comparative Example 2, The culture solution of Example 19 was compared as shown in Fig. In Figure 5, Peak 1 is Puerarin and Peak 4 is dihydrogenistein (DHG). Genistein is an unchanged ingredient in the 18th minute. As shown in FIG. 5, it was confirmed that the peak 4 of dihydrogenistein (DHG) was increased by eliminating the components of puerarin and peak 3 at peak 1.

National Academy of Agricultural Sciences KACC91829P 20130710

Claims (19)

Diadjene or genistein can be converted into dihydrodaidzein (DHD) or dihydrogenistein (DHG), respectively, by using Pediococcus pentosaceus ) EP106 (accession number: KACC91829P).
A method for producing a fermented product containing a dihydrolidase from a fermented extract using the strain of claim 1.
The method of claim 2,
The method comprises:
(a) an extraction step of extracting the pulverized liquor with ethanol; And
(b) a step of culturing the strain obtained in step (a) inoculating the strain of claim 1, followed by agitation thereof to prepare a culture solution; and a step of culturing the fermented product containing the dihydroididase.
The method of claim 3,
Wherein the stirring speed of the culturing step (b) is 100 to 300 rpm. ≪ RTI ID = 0.0 > 11. < / RTI >
The method of claim 3,
Wherein the temperature of the culture step (b) is 20 to 40 ° C.
The method of claim 3,
Wherein the culturing time of the step (b) is 20 to 80 hours. ≪ Desc / Clms Page number 19 >
The method of claim 3,
Wherein the extract is contained in an amount of 0.2 to 3% by weight based on the total amount of the culture in the step (b) of culturing the fermented product.
A method for producing a dihydrogenentyne-containing soybean embryo fermentation product from a soybean extract using the strain of claim 1.
The method of claim 8,
The method comprises:
(a) an extraction step of extracting pulverized soybean with ethanol; And
(b) a step of culturing the strain obtained in step (a) inoculating the strain of claim 1, followed by agitation to produce a culture solution; and (c) culturing the fermented soybean embryo.
The method of claim 8,
Wherein the stirring speed of the (b) culturing step is 100 to 300 rpm. ≪ RTI ID = 0.0 > 11. < / RTI >
The method of claim 8,
Wherein the temperature of the culture step (b) is 20 to 40 占 폚.
The method of claim 8,
Wherein the culture time of the step (b) is 20 to 80 hours. ≪ Desc / Clms Page number 20 >
The method of claim 8,
Wherein the extract comprises 0.2 to 3% by weight based on the total amount of the culture in the step (b) of culturing the fermented soybean embryo.
A fermented product produced by using the strain of claim 1.
A fermented fermented dried product produced by freeze-drying the fermented product of claim 14.
A pharmaceutical preparation comprising the fermentation product of claim 14, which is used for the prevention or treatment of menopausal disorders, osteoporosis, prostate cancer, prostate hyperplasia or female hormone control disorders.
A fermented soybean embryo produced using the strain of claim 1.
A freeze-dried fermented soybean embryo produced by freeze-drying the fermented soybean embryo of claim 17.
A pharmaceutical preparation comprising the fermented soybean embryo of claim 17 for use in the prevention or treatment of menopausal disorders, osteoporosis, prostate cancer, hyperplasia of the prostate, or female hormone control disorders.

Images